N@N

OSIR, ONTY, NVAX, NPHC, NLTX, NABI, Biomed - Genetics Stocks 43.65% undervalued

^{Published on 2011-01-26 12:41:49 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. OSIRIS THERAPEUTICS INC (NASDAQ:OSIR), ONCOTHYREON INC (NASDAQ:ONTY), NOVAVAX INC (NASDAQ:NVAX), NUTRA PHARMA CORP (OTCBB:NPHC), NILE THERAPEUTICS INC (NASDAQ:NLTX), NABI BIOPHARMACEUTICALS (NASDAQ:NABI) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     OSIR       OSIRIS THERAPEUTICS INC             7.13           12.65          43.65% undervalued          Biomed - Genetics      
     ONTY       ONCOTHYREON INC                     3.11           8.65           64.06% undervalued          Biomed - Genetics      
     NVAX       NOVAVAX INC                         2.26           3.22           29.87% undervalued          Biomed - Genetics      
     NPHC       NUTRA PHARMA CORP                   0.13           0.38           65.51% undervalued          Biomed - Genetics      
     NLTX       NILE THERAPEUTICS INC               0.51           1.02           49.76% undervalued          Biomed - Genetics      
     NABI       NABI BIOPHARMACEUTICALS             5.72           7.21           20.69% undervalued          Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

OSIRIS THERAPEUTICS INC (NASDAQ:OSIR) - Osiris Therapeutics, Inc., a stem cell therapeutic company, focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States and internationally. Its lead biologic drug candidate includes Prochymal, which is in Phase 3 clinical trials for the treatment of acute and steroid refractory graft versus host disease (GvHD) and Crohn's disease, as well as for the repair of gastrointestinal injury resulting from radiation exposure. The company is also developing its Prochymal drug candidate for the repair of heart tissue following a heart attack, and for the protection of pancreatic islet cells in patients with type 1 diabetes. In addition, it is developing Chondrogen, a biologic drug candidate for the treatment of osteoarthritis and the reduction of pain in the knee. Additionally, the company focuses on developing biologic products for use in surgical procedures. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for developing Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for the distribution of Prochymal for GvHD in Japan. Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, Maryland.

ONCOTHYREON INC (NASDAQ:ONTY) - Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses primarily on the development of therapeutic products for the treatment of cancer. Its product under development includes ONT-10, a synthetic MUC1-based liposomal glycolipopeptide cancer vaccine for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, and prostate, as well as in certain types of lung cancer. The company is also developing small molecule drugs, such as PX-866, a Phase I trial product for the patients with advanced metastatic cancer; and PX-478 that completed enrollment in a Phase I trial for the patients with advanced metastatic cancer. It operates in Canada, the United States, Barbados, and Europe. The company was founded in 1985 and is headquartered in Seattle, Washington.

NOVAVAX INC (NASDAQ:NVAX) - Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant vaccines for infectious diseases using its virus-like particle platform technology. Its vaccine product candidates target pandemic influenza, including H1N1 and H5N1 strains; seasonal influenza; Respiratory Syncytial Virus; and Varicella Zoster Virus that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza and H1N1 pandemic vaccine candidates, Cadilas biogeneric products, and other diagnostic products for the territory of India. It also has a co-marketing agreement with GE Healthcare for a pandemic influenza vaccine solution. The company was founded in 1987 and is headquartered in Rockville, Maryland.

NUTRA PHARMA CORP (OTCBB:NPHC) - Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma markets and sells Cobroxin and Nyloxin, non-narcotic treatments for moderate to severe chronic pain. It is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain. The company, through its subsidiary, ReceptoPharm, provides contract research services through its ISO class 5 and GMP certified facilities. Its wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates. Nutra Pharma Corporation was founded in 2000 and is based in Coral Springs, Florida.

NILE THERAPEUTICS INC (NASDAQ:NLTX) - As of September 17, 2007, SMI Products Inc. was acquired by Nile Therapeutics, Inc in a reverse merger transaction. SMI Products, Inc. does not have significant operations. Previously, the company provided Internet real estate mortgage services. It seeks potential targets for a business combination through the purchase of assets, share purchase or exchange, merger, or similar type of transaction. SMI Products was founded in 1996 and is based in Santa Monica, California. As of August 11, 2006, SMI Products, Inc. is a subsidiary of Fountainhead Capital Partners Limited.

NABI BIOPHARMACEUTICALS (NASDAQ:NABI) - Nabi Biopharmaceuticals, a biopharmaceutical company, develops vaccines addressing unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine under Phase III clinical trial for treatment of nicotine addiction and prevention of smoking relapse. It has collaboration agreements with the National Institute of Allergy and Infectious Diseases, and National Institute for Drug Abuse; a research and development agreement with the U.S. Department of Defense; and license agreements with National Institutes of Health, Brookhaven National Labs, and University of Maryland. The company was founded in 1967 and is headquartered in Rockville, Maryland.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net